September 13, 2016 — Results from a new study suggest that small molecules known as microRNAs may be part of the pathway connecting inflammation with increased heart disease risk in obese people. The new findings were presented at the American Physiological Society’s Inflammation, Immunity and Cardiovascular Disease conference, Aug. 24-27 in Westminster, Colo.

bundled payments for cardiology, CMS cardiac reimbursements
bundled payments for cardiology, CMS cardiac reimbursements
bundled payments for cardiology, CMS cardiac reimbursements

(Editor’s note: This is the first part of a two-part series on the proposed Medicare five-year demonstration for mandatory bundled payment system. Part 1 outlines the baseline capability requirements. Part 2 presents a model methodology for developing a successful cardiac bundle the payment model as it applies to cardiac patients.)

September 13, 2016 — Findings from a small study suggest that people who followed the popular Paleo diet for only eight weeks experienced positive effects on heart health. Preliminary findings from this research were presented at the American Physiological Society’s Inflammation, Immunity and Cardiovascular Disease conference Aug. 24-27 in Westminster, Colo.

August 29, 2016 — SynCardia Systems, manufacturer of the Total Artificial Heart (TAH), announced that the judge overseeing its Chapter 11 reorganization has approved the conditions for the bankruptcy process.

The judge approved the following:

The American Medical Society for Sports Medicine (AMSSM) last week released a new position statement on cardiovascular pre-participation screening for athletes. The statement discusses current evidence and knowledge gaps while offering recommendations and future directions.

September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.2M ($18.3M). The funding will support European commercialization of the company’s PerQseal technology to meet the growing demand for absorbable, percutaneous vessel closure products, as well as execution of a U.S. Food and Drug Administration (FDA) regulatory study.

A Saint Louis University researcher has received a grant to study the effects of treating post-traumatic stress disorder (PTSD) on cardiovascular and metabolic health. Jeffrey Scherrer, Ph.D., associate professor in Family and Community Medicine, received $2,348,320 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).

Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow Veniti to complete the VIRTUS Trial and regulatory filing for the Vici Venous Stent System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.

September 9, 2016 — New research published Sept. 8 in the Open Access journal PLOS Biology reports the role of genes in congenital heart defects (CHD) is more complex than previously realized. The research conducted University of California Irvine biologists Anne Calof and Arthur Lander and colleagues also found that overall risk is determined by a combination of gene effects both inside and outside of the heart itself.

Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL study has been carried out. The implantation was conducted in accordance with the authorizations obtained from the ANSM (French national agency for the safety of medicines and health products) and CPP (patient protection committee).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now